17.16 USD
+0.50 (+3.01%)
AT CLOSE (11:59 AM EDT)
uniQure N.V. (QURE)
NASDAQ: QURE • USD
17.10
-0.06 (-0.35%)
POST MARKET (AS OF 07:55 PM EDT)
Market: CLOSED
Open?$16.60
High?$17.55
Low?$16.55
Prev. Close?$17.16
Volume?1.2M
Avg. Volume?4.7M
VWAP?$17.09
Rel. Volume?0.25x
Bid / Ask
Bid?$16.50 × 100
Ask?$17.21 × 100
Spread?$0.71
Midpoint?$16.86
Valuation & Ratios
Market Cap?1.1B
Shares Out?62.5M
Float?59.4M
Float %?95.3%
P/E Ratio?N/A
P/B Ratio?5.39
EPS?-$3.18
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?10.43Strong
Quick Ratio?10.43Strong
Cash Ratio?1.28Strong
Debt/Equity?0.25Low
ValuationFAIRLY VALUED
Score58/100
P/E?N/A▾
P/B?5.39FAIR▾
P/S?66.65HIGH▾
P/FCF?N/A▾
EV/EBITDA?-6.1CHEAP▾
EV/Sales?64.76HIGH▾
Returns & Efficiency
ROE?-100.0%WEAK▾
ROA?-24.1%WEAK▾
Cash Flow & Enterprise
FCF?$-178402000
Enterprise Value?$1.0B
Related Companies
Loading...
News
Profile
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
Address
PAASHEUVELWEG 25A
AMSTERDAM, 1105 BP
Phone: 1-339-970-7000
AMSTERDAM, 1105 BP
Phone: 1-339-970-7000